$1.2 Billion is the total value of Sarissa Capital Management LP's 13 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDCO | MEDICINES CO | $356,917,000 | +69.9% | 4,202,000 | 0.0% | 29.62% | +12.5% | |
| BIIB | BIOGEN INC | $190,797,000 | +27.5% | 643,000 | 0.0% | 15.84% | -15.6% | |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $137,186,000 | +58.2% | 10,307,000 | +2.0% | 11.39% | +4.8% |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS INC | $106,571,000 | +88.7% | 860,000 | +1.1% | 8.85% | +25.0% |
| AGN | Sell | ALLERGAN PLC | $89,371,000 | -49.1% | 467,500 | -55.2% | 7.42% | -66.3% |
| INVA | INNOVIVA INC | $88,386,000 | +34.3% | 6,242,000 | 0.0% | 7.34% | -11.0% | |
| ALKS | New | ALKERMES PLC | $77,622,000 | – | 3,805,000 | +100.0% | 6.44% | – |
| New | MEDICINES COnote 3.500% 1/1 | $68,377,000 | – | 20,000,000 | +100.0% | 5.68% | – | |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $66,205,000 | +113.5% | 443,500 | +83.3% | 5.50% | +41.4% |
| MRSN | MERSANA THERAPEUTICS INC | $21,487,000 | +262.6% | 3,750,000 | 0.0% | 1.78% | +140.0% | |
| RGLS | REGULUS THERAPEUTICS INC | $1,648,000 | +23.6% | 1,851,851 | 0.0% | 0.14% | -18.0% | |
| MRTX | MIRATI THERAPEUTICS INC | $128,000 | +66.2% | 1,000 | 0.0% | 0.01% | +10.0% | |
| ABBV | ABBVIE INC | $88,000 | +17.3% | 1,000 | 0.0% | 0.01% | -22.2% | |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC. | $0 | – | -1,417,000 | -100.0% | -1.91% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.